CD274 and neoplasm: Specifically, the combination therapy reduced tumor volume by 40.5% compared to αPD‐L1 therapy alone, underscoring the clinical potential of targeting NAD+ metabolism to enhance the efficacy of anti‐PD‐L1 immunotherapy in CC.